中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2011年
25期
23-25
,共3页
邬云红%唐蜀西%达娃普尺
鄔雲紅%唐蜀西%達娃普呎
오운홍%당촉서%체왜보척
血脂异常%藏族%C反应蛋白质%阿托伐他汀%辛伐他汀
血脂異常%藏族%C反應蛋白質%阿託伐他汀%辛伐他汀
혈지이상%장족%C반응단백질%아탁벌타정%신벌타정
Dyslipidemias%Zang nationality%C-reactive protein%Atorvastatin%Simvastatin
目的 评价阿托伐他汀10 mg和辛伐他汀20 mg对2型糖尿病合并血脂异常的藏族患者降脂疗效和对血清高敏C反应蛋白( hs-CRP)的影响。方法 选择2型糖尿病合并血脂异常的藏族患者70例，按随机数字表法分为阿托伐他汀10 mg组和辛伐他汀20mg组，每组35例。治疗前和治疗后4周分别测定总胆固醇(TC)、低密度脂蛋白胆固醇( LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、载脂蛋白B(ApoB)、白细胞(WBC)计数、空腹血糖(FBG)和hs-CRP水平，并观察两组的不良反应。结果 治疗后4周，两组TC、LDL-C、ApoB均较治疗前显著下降(P＜0.01)。阿托伐他汀10 mg组治疗后4周TG水平较治疗前显著降低[(1.39±0.63) mmol/L比(1.95±1.62) mmol/L，P＜0.05]，而辛伐他汀20 mg组治疗后4周TG水平有下降趋势但差异无统计学意义[(1.72±0.32)nnol/L比(1.93±0.83) mmol/L，P＞0.05]。两组治疗后hs-CRP水平均较治疗前显著降低，阿托伐他汀10mg组hs-CRP水平降低幅度大于辛伐他汀20mg组（40.51％比35.34％），差异有统计学意义(P＜ 0.05)。逐步回归分析表明,hs-CRP水平的降低独立于降脂效果，仅与他汀种类相关（标准化回归系数=-0.384，P=0.022）。结论 辛伐他汀20 mg对于血清TC和LDL-C水平的降低作用与阿托伐他汀10 mg相当，两种他汀类药物均可降低藏族2型糖尿病患者hs-CRP水平，阿托伐他汀疗效略优于辛伐他汀。
目的 評價阿託伐他汀10 mg和辛伐他汀20 mg對2型糖尿病閤併血脂異常的藏族患者降脂療效和對血清高敏C反應蛋白( hs-CRP)的影響。方法 選擇2型糖尿病閤併血脂異常的藏族患者70例，按隨機數字錶法分為阿託伐他汀10 mg組和辛伐他汀20mg組，每組35例。治療前和治療後4週分彆測定總膽固醇(TC)、低密度脂蛋白膽固醇( LDL-C)、高密度脂蛋白膽固醇(HDL-C)、三酰甘油(TG)、載脂蛋白B(ApoB)、白細胞(WBC)計數、空腹血糖(FBG)和hs-CRP水平，併觀察兩組的不良反應。結果 治療後4週，兩組TC、LDL-C、ApoB均較治療前顯著下降(P＜0.01)。阿託伐他汀10 mg組治療後4週TG水平較治療前顯著降低[(1.39±0.63) mmol/L比(1.95±1.62) mmol/L，P＜0.05]，而辛伐他汀20 mg組治療後4週TG水平有下降趨勢但差異無統計學意義[(1.72±0.32)nnol/L比(1.93±0.83) mmol/L，P＞0.05]。兩組治療後hs-CRP水平均較治療前顯著降低，阿託伐他汀10mg組hs-CRP水平降低幅度大于辛伐他汀20mg組（40.51％比35.34％），差異有統計學意義(P＜ 0.05)。逐步迴歸分析錶明,hs-CRP水平的降低獨立于降脂效果，僅與他汀種類相關（標準化迴歸繫數=-0.384，P=0.022）。結論 辛伐他汀20 mg對于血清TC和LDL-C水平的降低作用與阿託伐他汀10 mg相噹，兩種他汀類藥物均可降低藏族2型糖尿病患者hs-CRP水平，阿託伐他汀療效略優于辛伐他汀。
목적 평개아탁벌타정10 mg화신벌타정20 mg대2형당뇨병합병혈지이상적장족환자강지료효화대혈청고민C반응단백( hs-CRP)적영향。방법 선택2형당뇨병합병혈지이상적장족환자70례，안수궤수자표법분위아탁벌타정10 mg조화신벌타정20mg조，매조35례。치료전화치료후4주분별측정총담고순(TC)、저밀도지단백담고순( LDL-C)、고밀도지단백담고순(HDL-C)、삼선감유(TG)、재지단백B(ApoB)、백세포(WBC)계수、공복혈당(FBG)화hs-CRP수평，병관찰량조적불량반응。결과 치료후4주，량조TC、LDL-C、ApoB균교치료전현저하강(P＜0.01)。아탁벌타정10 mg조치료후4주TG수평교치료전현저강저[(1.39±0.63) mmol/L비(1.95±1.62) mmol/L，P＜0.05]，이신벌타정20 mg조치료후4주TG수평유하강추세단차이무통계학의의[(1.72±0.32)nnol/L비(1.93±0.83) mmol/L，P＞0.05]。량조치료후hs-CRP수평균교치료전현저강저，아탁벌타정10mg조hs-CRP수평강저폭도대우신벌타정20mg조（40.51％비35.34％），차이유통계학의의(P＜ 0.05)。축보회귀분석표명,hs-CRP수평적강저독립우강지효과，부여타정충류상관（표준화회귀계수=-0.384，P=0.022）。결론 신벌타정20 mg대우혈청TC화LDL-C수평적강저작용여아탁벌타정10 mg상당，량충타정류약물균가강저장족2형당뇨병환자hs-CRP수평，아탁벌타정료효략우우신벌타정。
Objective To evaluate the effects of atorvastatin 10 mg or simvastatin 20 mg on serum lipids and high sensitive C-reactive protein (hs-CRP) in Tibetan type 2 diabetic patients with dyslipidemias.Methods Seventy Tibetan type 2 diabetic patients with dyslipidemias were divided into two groups by random number table: atorvastatin 10 mg group(35 cases,treated with atorvastatin 10 mg/d) and simvastatin 20 mg group (35 cases, treated with simvastatin 20 mg/d). Before and 4 weeks after treatment, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), apolipoprotein B (ApoB), white blood cell (WBC) count, fasting blood glucose (FBG) and hs-CRP were measured and adverse reactions were observed. Results After treatment for 4 weeks, the levels of TC, LDL-C and ApoB were significantly decreased in two groups (P＜ 0.01 ), and the level of TG was significantly decreased in atorvastatin 10 mg group [( 1.39 + 0.63 ) mmol/L vs. ( 1.95 ±1.62) mmol/L,P＜0.05], but was not significantly decreased in simvastatin 20 mg group [(1.72 ±0.32)mmol/L vs. ( 1.93 ± 0.83 ) mmol/L,P ＞ 0.05]. The level of hs-CRP was significantly decreased in two groups (P ＜ 0.05), and the decreased range in atorvastatin 10 mg group was higher than that in simvastatin 20 mg group (40.51％ vs. 35.34％ ,P ＜ 0.05). Stepwise regression analysis showed that the decreased hs-CRP was independent of reduced serum lipids and had relationship with the kinds of statins (B =-0.384,P=0.022).Conclusions The effects of simvastatin on serum TC, LDL-C are the same as atorvastatin. Both have significant anti-inflammatory effects, while the degree of hs-CRP reducing by atorvastatin 10 mg is higher than that by simvastatin 20 mg in Tibetan type 2 diabetes.
